March 4, 2019 09:24 AM EST

In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data

As Novo Nordisk hustles up an oral version of its GLP-1 diabetes drug Ozempic for FDA review, the big Eli Lilly competitor has posted another …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In a block­buster fran­chise race, No­vo’s Trulic­i­ty ri­val scores more promis­ing late-stage di­a­betes da­ta